Inhibition of SARS-CoV-2 replication by a ssDNA aptamer targeting the nucleocapsid protein
The nucleocapsid protein of SARS-CoV-2 plays significant roles in viral assembly, immune evasion, and viral stability. Due to its immunogenicity, high expression levels during COVID-19, and conservation across viral strains, it represents an attractive target for antiviral treatment. In this study, we identified and characterized a single-stranded DNA aptamer, N-Apt17, which effectively disrupts the liquid-liquid phase separation (LLPS) mediated by the N protein. To enhance the aptamer's stability, a circular bivalent form, cb-N-Apt17, was designed and evaluated. Our findings demonstrated that cb-N-Apt17 exhibited improved stability, enhanced binding affinity, and superior inhibition of N protein LLPS; thus, it has the potential inhibition ability on viral replication. These results provide valuable evidence supporting the potential of cb-N-Apt17 as a promising candidate for the development of antiviral therapies against COVID-19.IMPORTANCEVariants of SARS-CoV-2 pose a significant challenge to currently available COVID-19 vaccines and therapies due to the rapid epitope changes observed in the viral spike protein. However, the nucleocapsid (N) protein of SARS-CoV-2, a highly conserved structural protein, offers promising potential as a target for inhibiting viral replication. The N protein forms complexes with genomic RNA, interacts with other viral structural proteins during virion assembly, and plays a critical role in evading host innate immunity by impairing interferon production during viral infection. In this investigation, we discovered a single-stranded DNA aptamer, designated as N-Apt17, exhibiting remarkable affinity and specificity for the N protein. Notably, N-Apt17 disrupts the liquid-liquid phase separation (LLPS) of the N protein. To enhance the stability and molecular recognition capabilities of N-Apt17, we designed a circular bivalent DNA aptamer termed cb-N-Apt17. In both in vivo and in vitro experiments, cb-N-Apt17 exhibited increased stability, enhanced binding affinity, and superior LLPS disrupting ability. Thus, our study provides essential proof-of-principle evidence supporting the further development of cb-N-Apt17 as a therapeutic candidate for COVID-19.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Microbiology spectrum - 12(2024), 4 vom: 02. Apr., Seite e0341023 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Huang, Yanping [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiviral Agents |
---|
Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1128/spectrum.03410-23 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368664201 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368664201 | ||
003 | DE-627 | ||
005 | 20240408232411.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240220s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1128/spectrum.03410-23 |2 doi | |
028 | 5 | 2 | |a pubmed24n1369.xml |
035 | |a (DE-627)NLM368664201 | ||
035 | |a (NLM)38376366 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Huang, Yanping |e verfasserin |4 aut | |
245 | 1 | 0 | |a Inhibition of SARS-CoV-2 replication by a ssDNA aptamer targeting the nucleocapsid protein |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.04.2024 | ||
500 | |a Date Revised 08.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The nucleocapsid protein of SARS-CoV-2 plays significant roles in viral assembly, immune evasion, and viral stability. Due to its immunogenicity, high expression levels during COVID-19, and conservation across viral strains, it represents an attractive target for antiviral treatment. In this study, we identified and characterized a single-stranded DNA aptamer, N-Apt17, which effectively disrupts the liquid-liquid phase separation (LLPS) mediated by the N protein. To enhance the aptamer's stability, a circular bivalent form, cb-N-Apt17, was designed and evaluated. Our findings demonstrated that cb-N-Apt17 exhibited improved stability, enhanced binding affinity, and superior inhibition of N protein LLPS; thus, it has the potential inhibition ability on viral replication. These results provide valuable evidence supporting the potential of cb-N-Apt17 as a promising candidate for the development of antiviral therapies against COVID-19.IMPORTANCEVariants of SARS-CoV-2 pose a significant challenge to currently available COVID-19 vaccines and therapies due to the rapid epitope changes observed in the viral spike protein. However, the nucleocapsid (N) protein of SARS-CoV-2, a highly conserved structural protein, offers promising potential as a target for inhibiting viral replication. The N protein forms complexes with genomic RNA, interacts with other viral structural proteins during virion assembly, and plays a critical role in evading host innate immunity by impairing interferon production during viral infection. In this investigation, we discovered a single-stranded DNA aptamer, designated as N-Apt17, exhibiting remarkable affinity and specificity for the N protein. Notably, N-Apt17 disrupts the liquid-liquid phase separation (LLPS) of the N protein. To enhance the stability and molecular recognition capabilities of N-Apt17, we designed a circular bivalent DNA aptamer termed cb-N-Apt17. In both in vivo and in vitro experiments, cb-N-Apt17 exhibited increased stability, enhanced binding affinity, and superior LLPS disrupting ability. Thus, our study provides essential proof-of-principle evidence supporting the further development of cb-N-Apt17 as a therapeutic candidate for COVID-19 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a antiviral therapy | |
650 | 4 | |a aptamer | |
650 | 4 | |a nucleocapsid protein | |
650 | 7 | |a Nucleocapsid Proteins |2 NLM | |
650 | 7 | |a DNA, Single-Stranded |2 NLM | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
700 | 1 | |a Huang, Congcong |e verfasserin |4 aut | |
700 | 1 | |a Chen, Junkai |e verfasserin |4 aut | |
700 | 1 | |a Chen, Siwei |e verfasserin |4 aut | |
700 | 1 | |a Li, Bei |e verfasserin |4 aut | |
700 | 1 | |a Li, Jian |e verfasserin |4 aut | |
700 | 1 | |a Jin, Zhixiong |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Qiwei |e verfasserin |4 aut | |
700 | 1 | |a Pan, Pan |e verfasserin |4 aut | |
700 | 1 | |a Du, Weixing |e verfasserin |4 aut | |
700 | 1 | |a Liu, Long |e verfasserin |4 aut | |
700 | 1 | |a Liu, Zhixin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Microbiology spectrum |d 2013 |g 12(2024), 4 vom: 02. Apr., Seite e0341023 |w (DE-627)NLM241847044 |x 2165-0497 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:e0341023 |
856 | 4 | 0 | |u http://dx.doi.org/10.1128/spectrum.03410-23 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2024 |e 4 |b 02 |c 04 |h e0341023 |